MADRIGAL PHARMACEUTICALS, INC. Interest Expense, Debt, Excluding Amortization
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Interest Expense, Debt, Excluding Amortization of $135.84 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseDebtExcludingAmortization · last filed 2026-02-19
- MADRIGAL PHARMACEUTICALS, INC. interest expense, debt, excluding amortization for the quarter ending 2025-03-31 was $25.21M, a 26.35% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. interest expense, debt, excluding amortization for the quarter ending 2024-12-31 was -$4.18M.
- MADRIGAL PHARMACEUTICALS, INC. interest expense, debt, excluding amortization for the quarter ending 2024-09-30 was -$4.46M, a 412.24% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. interest expense, debt, excluding amortization for the quarter ending 2024-06-30 was -$3.22M, a 249.12% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. interest expense, debt, excluding amortization for fiscal 2025 was $135.84M, a 507.48% increase from fiscal 2024.
- MADRIGAL PHARMACEUTICALS, INC. interest expense, debt, excluding amortization for fiscal 2024 was $22.36M, a 9.25% decline from fiscal 2023.
- MADRIGAL PHARMACEUTICALS, INC. interest expense, debt, excluding amortization for fiscal 2023 was $24.64M, a 44.95% increase from fiscal 2022.
- MADRIGAL PHARMACEUTICALS, INC. interest expense, debt, excluding amortization for fiscal 2022 was $17.00M.
| Period end | Interest Expense, Debt, Excluding Amortization 3 month | Interest Expense, Debt, Excluding Amortization 6 month | Interest Expense, Debt, Excluding Amortization 9 month | Interest Expense, Debt, Excluding Amortization 12 month |
|---|---|---|---|---|
| 2025-12-31 | $135.84M 10-K · filed 2026-02-19 | |||
| 2025-03-31 | $25.21M 10-Q · filed 2025-05-01 | $21.02M derived: sum of 2 quarters · filed 2025-05-01 | $16.56M derived: sum of 3 quarters · filed 2025-05-01 | $13.34M derived: sum of 4 quarters · filed 2025-05-01 |
| 2024-12-31 | -$4.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$8.65M derived: sum of 2 quarters · filed 2025-02-26 | -$11.86M derived: sum of 3 quarters · filed 2025-02-26 | $22.36M 10-K · filed 2025-02-26 |
| 2024-09-30 | -$4.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$7.68M derived: sum of 2 quarters · filed 2024-10-31 | $26.54M 10-Q · filed 2024-10-31 | $23.45M derived: sum of 4 quarters · filed 2024-10-31 |
| 2024-06-30 | -$3.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $31.01M 10-Q · filed 2024-08-07 | $27.91M derived: sum of 3 quarters · filed 2024-08-07 | $29.34M derived: sum of 4 quarters · filed 2024-08-07 |
| 2024-03-31 | $34.23M 10-Q · filed 2024-05-07 | $31.13M derived: sum of 2 quarters · filed 2024-05-07 | $32.56M derived: sum of 3 quarters · filed 2024-05-07 | $34.72M derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | -$3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$1.67M derived: sum of 2 quarters · filed 2024-02-28 | $492.00K derived: sum of 3 quarters · filed 2024-02-28 | $24.64M 10-K · filed 2024-02-28 |
| 2023-09-30 | $1.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $3.59M derived: sum of 2 quarters · filed 2023-11-06 | $27.74M 10-Q · filed 2023-11-06 | $29.55M derived: sum of 4 quarters · filed 2023-11-06 |
| 2023-06-30 | $2.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $26.31M 10-Q · filed 2023-08-08 | $28.12M derived: sum of 3 quarters · filed 2023-08-08 | $29.26M derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | $24.15M 10-Q · filed 2023-05-09 | $25.96M derived: sum of 2 quarters · filed 2023-05-09 | $27.10M derived: sum of 3 quarters · filed 2023-05-09 | |
| 2022-12-31 | $1.82M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-03 | $2.95M derived: sum of 2 quarters · filed 2023-03-03 | $17.00M 10-K/A · filed 2023-03-03 | |
| 2022-09-30 | $1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $15.18M 10-Q · filed 2022-11-03 | ||
| 2022-06-30 | $14.05M 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |